Clinical studies have also shown that a switch in NSCLC differentiation to a NE phenotype is associated with emergent treatment resistance to epidermal growth factor (EGFR) and other tyrosine kinase inhibitors (TKIs) [51]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.